FORTY
Research type
Research Study
Full title
Favourable Outcomes of canceR TherapY
IRAS ID
270223
Contact name
Thomas Mee
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The aim of this project is to use the latest available cancer data, which has very high coverage of England, to update the contribution of the three main cancer treatments (surgery, radiotherapy and chemotherapy). Currently, it is considered that radiotherapy (RT) is the predominant treatment in 40% of patients cured of their cancer, used alone or in combination with other treatments. The figures for surgery and chemotherapy are 49% and 11% respectively. The original source of these figures date from 1992, based on data from the preceding decade.
We will investigate the relationship between the contributions to cure and population factors, such as age, which are known to affect how many patients are treated and their survival. Individual tumour characteristics, such as cancer grade, will not be included in this study. Additionally, we aim to investigate whether there are cohorts of patients who do not survive long even after treatment that was intended to cure them.
This study will cover all cancer types and only uses depersonalised data previously collected and held by the National Cancer Registration and Analysis Service.REC name
South Central - Berkshire Research Ethics Committee
REC reference
19/SC/0484
Date of REC Opinion
28 Aug 2019
REC opinion
Favourable Opinion